{"name":"Cipla Ltd.","slug":"cipla-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":400000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Tasigna","genericName":"NILOTINIB","slug":"nilotinib","revenue":400000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2007-01-01","label":"Tasigna first approved","drug":"Tasigna","drugSlug":"nilotinib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":400000000,"percentOfTotal":100,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Tasigna","genericName":"NILOTINIB","slug":"nilotinib","indication":"Chronic Myelocytic Leukemia Accelerated Phase","status":"marketed","revenue":400000000},{"name":"EU-sourced Avastin®","genericName":"EU-sourced Avastin®","slug":"eu-sourced-avastin","indication":"Metastatic colorectal cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CBT124","genericName":"CBT124","slug":"cbt124","indication":"unknown","status":"phase_3"}]}],"pipeline":[{"name":"Tasigna","genericName":"NILOTINIB","slug":"nilotinib","phase":"marketed","mechanism":"Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML.","indications":["Chronic Myelocytic Leukemia Accelerated Phase","Chronic phase chronic myeloid leukemia","Philadelphia Chromosome Positive Chronic Myelocytic Leukemia"],"catalyst":""},{"name":"CBT124","genericName":"CBT124","slug":"cbt124","phase":"phase_3","mechanism":"CBT124 is a small molecule that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"EU-sourced Avastin®","genericName":"EU-sourced Avastin®","slug":"eu-sourced-avastin","phase":"phase_3","mechanism":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic breast cancer","Glioblastoma","Metastatic renal cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNcWRjUW5LYjh4SzBqeHpScGlndGlERnBnc1dwRmhpOUxkZGgtaGN6WVFfZGExcU9DUURnQmp4SHNBMnVOTUhZOEhxU0JXZjNEajhYNjBjTjZDSnZhOXN6SGlWQW5nb3ZtZUhqQkx5WWY5dG1hM1lTRG1UVHNmeHY1Z2FIUXkzSk8yYkNsOGhGSVZEdjlzdEE3R0RzT00xcW9NTEgyY2l5UEUxTGJUbm05MjgxakZhRDFaeklCOA?oc=5","date":"2026-04-06","type":"pipeline","source":"AD HOC NEWS","summary":"Cipla Ltd stock: Why it's facing headwinds despite pharma strengths - AD HOC NEWS","headline":"Cipla Ltd stock: Why it's facing headwinds despite pharma strengths","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxObEl4MzhKTkhsdUVjZ0NPZXNNQkVJUmxkcEJrUWowZGM4Z1R4TnZncU5DT0JfV0lfR3YyalBZTmxUUFd3c0lRUGgzeDlKMWZKTHR6WU4ybmRnc012MEFRRzdMVzhZYlZ0d0VVNHB6RC1OMjBuWjM0UmdON3NoSlBmenpKTFlhQlJxd05fd1NWaU5nQjlPbnIxOThCd1BMOXdQR3lnMUJJVmpWUjM5WDlsT3F2a1kxZ2ZIbk5MNmZtd2Z5dw?oc=5","date":"2026-04-06","type":"pipeline","source":"Markets Mojo","summary":"Cipla Ltd. Sees Sharp Open Interest Surge Amid Bearish Price Action - Markets Mojo","headline":"Cipla Ltd. Sees Sharp Open Interest Surge Amid Bearish Price Action","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPd2Zwcm9QSXVaWU5pWFNYZVh6NUZUOWt1LWJhZGhORFlmWDMtOHhvMXFfXzlNdVZJMEpXYUVtcTJwMjlEUjJjVGZybDY3Qmd5ZmhvQ2VpbDNEVkFuaWJLR2x5NHYtSF9lTHVsYWR1MXFfNlNrOVZ3REQ0aXJuT01ZZlFVYUh6Q2wxODFzYktTSHJFTm1rYU1ld3A4c3poVDNENFRYWHR6RDRqQlF1RDdkcFhOMXFFZlFFc2dlbWJLbldFRXdPa25sb0J0SmUtbDVQNDNzSURQeEV0R2xPNXFuLWZONExjQ1p4b0JkUUJRNFlXN2N6?oc=5","date":"2026-04-03","type":"regulatory","source":"BioSpace","summary":"Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis - BioSpace","headline":"Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary F","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPWG1IYl9Ia3hUWUFBSmc5QVUta2xUWWRXV2lvNXdBN1gtTm5IR2R0c1RXQXUzS196SjBNR1NMbHdFa3pfeHM1Mm1fVjc2OXdFSkRSMnpnZEQ1QV9GanNoRmFmVnBpWUxvQ3JoV2J6V3ZVOGpLTUxvMkE2OEtFU1FsTVVhZVZCQWFVRGdvY1FEQVZOZ25yOEVzZHhaaHR2clRKYVJHdTluVl9iSjQ5Yk5PY3ZOQjZwc3JUUnFYUUMxd9IBckFVX3lxTE9TbU9FUVAtTEdGMkhScGE0VHZfWFVxU3ZVdjZWalpHTmpFUnJiMEpCZ0hIa3dkbG0ySEc3S09ERWdXRl8xSlVGVmNOTmZ5Y1FNLUFuN1YyS3RaYzhtRWJ2ZnBBSlMwTmVNYzk3NzZaTjNPdw?oc=5","date":"2026-03-17","type":"patent","source":"Law360","summary":"Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033 - Law360","headline":"Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033 - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNbTBCUGhwQThBSklfOVVOSUlKMmZOUzAzcnJHYmNwNm00ZHFNTHdkbkZ6aGJCZkNwa2E0N3JrbWJwWTd1Mk9yZFUzSjk5LTBUTHBDOUJHeUY1LThpZ0JfcVBMejU4aC1MeGVJaEhMUjhrNlNPRmkwZjlpZEtKNDdyN2I2LUtJYVlOX3p3cUQtYkQ0MFNOckJDMzM3WkV0b0VWTml4dTdrYXRUeU11d3dDNUtEZTB3aWpHR1E?oc=5","date":"2026-03-16","type":"deal","source":"Stock Titan","summary":"Patent deal delays PEDMARK generic, drug for chemo hearing loss, to 2033 - Stock Titan","headline":"Patent deal delays PEDMARK generic, drug for chemo hearing loss, to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNTXNLaE9KMzA0NUt3d1dBRk9ZSjBKQmpsMU9idENCdFVyQkZWM2d2bUcyMkxYSHBtTl9XWE92bVM5Q3ZwcHA4eE52Yzc1X2pSeXdGMllBMk9KTzZNYy1qenVCUEk3UzFoTkJpZGRCYTk2bmRyRFRsQnF0SG1ZV3dCb21Ecm02TkxnZWszOHUtSlV6TXh6WHVESGo1Rk9yazVXWk5WT0xXZk5ac2RwN2VRMF9rakd4UkhTa2FpTHNjRHZDMmc3dmNZcFFHVW5Gem5zT19GNXVMVVRaTVFGMmd4UTRTVlBxRFRkci1wX0d3WnlwRzc0cXdad0NLY0o4RExaZV84?oc=5","date":"2026-02-27","type":"patent","source":"PR Newswire","summary":"Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy - PR Newswire","headline":"Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxONmtKVXJsUVhaS0tQZlBKV1ZGeU1faTJ2TFdEaGx5Ri1ZcGktS2FxOTlpdVY1cUROc2pkQ01QdWFQSlFLalExSlN2Ujc3S0lSdHRRNTVrcG5WdG14cEdkWlk5cUpXNmp3VG00eHZIc1pZWmhESmxORmM3QVh0endqbk5hOUY5bWx5RE1uanpkRWM1bF9Wc0loS0tzdGpGQ1h4YUE?oc=5","date":"2026-02-17","type":"deal","source":"LinkedIn","summary":"\"The reason we chose Cipla for partnership is that it has a strong distribution network across India. They have reach in areas we are not located. This will help us reach more patients,\" said Winselow","headline":"\"The reason we chose Cipla for partnership is that it has a strong distribution network across India. They have reach in","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-01","type":"pipeline","source":"Medical Dialogues","summary":"Torrent Pharma Appoints Former Cipla Global CTO Geena Malhotra as Chief Technology Officer - Medical Dialogues","headline":"Torrent Pharma Appoints Former Cipla Global CTO Geena Malhotra as Chief Technology Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2026-01-26","type":"regulatory","source":"The Economic Times","summary":"Sun Pharma, Cipla recall products in US over manufacturing issues: USFDA - The Economic Times","headline":"Sun Pharma, Cipla recall products in US over manufacturing issues: USFDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQeEJ4cFFXLVBqTmlKQl9rNm9qRU93Y3NRZGx0bnB4djh1LVlvSVlSWk1MU3BYNzFubEVrUllYVm9fb2pRaGFiaHpVdERtSUxhUWFNdXdwS0hMRmloYTJTUXJFeGtPOGdqRFZqV2dfU0xUV1pYclZSWHY2LUV2Qk5QUDM0eHFHZElOYnY4T2pLSm12NzRST3FlczMycFdkVGVnMTJYSNIBrAFBVV95cUxQZDQ3NWlLQWNFX3kzOUJzcDd3VHFlVXVlWUVTM29SN3pEZ3UzODJ1b0ltU3BNTTJ5SldmbjF6SGRDLVdwZTkyOHdLeWllczhnQUNhVWpQeGk2SkpKSk5JcWh0RHpSV0R2d1V2emRGVG1CVGI0QnRGLTVMRzk2YzAwX2xqUkVLN05Odmp0VXVlNTRDN3ZENW5sQUhYeWhDU1ByUW9JOWlUdnU0VUpi?oc=5","date":"2026-01-26","type":"pipeline","source":"NDTV","summary":"Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues - NDTV","headline":"Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNZTNyMWVReUtIaGZBd0t6anNBakNuaEZBRnhvU0g1X2E2RE9YUFZWZUFvXzdFUTk3UUN3UTlOcWVRMmxwNkxOVU1SbmRGR0JQZmZ0bWxSNWs1SldzbURqVzREekJtSlVESGNGTGJHeXdoX2RiYktVM01BdTN3V04wdW9UbFRCQ1otXzMzS1dBSGjSAZgBQVVfeXFMTVJNTVdMYzF2NExyMmJ1SlFLVEh0MnN4Y1piQ3ZDVXBSNUVJVmZyLUlqcjdlMXpMYVZmdk1RTXFSQ1ZlbnlaZUR1ZUxOTjlyX2c0YnBhd0ppRHBzTUtFTWxwbkpMcks1Nkd4T2xXeFhvQzhlMlZiakpMNjlsS2U4ck9pUW85UXVqbmg2MlBtdGhwU3V2MGd2aEs?oc=5","date":"2026-01-26","type":"regulatory","source":"NDTV Profit","summary":"Sun Pharma, Cipla Recall Products In US: FDA - NDTV Profit","headline":"Sun Pharma, Cipla Recall Products In US: FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQN19yUjZmUzFBbWZwSUVLUU1IRkRFMFp3N0lPT0tjWFFhUVRMZG1xcHJicUM5S3BEZU9QWEpQNHQzbUZDVEVwOFpJOGItV01xZHJ3RWdmWnlVY1d2WVZ6ajV5SlhZU1Q4SWNmR1UyZFdkN0hHOG9UTGg0bndFMGJwZE1qTTVLU0dkR2VPcE5nT2N1b016R1pHSzRVZGc2T3p5Y3ctdTZieWhFNW9ZbllPcWl0aENacmI3VXg0dTBtV2d6TjJ2M2c?oc=5","date":"2026-01-23","type":"earnings","source":"Reuters","summary":"India's Cipla posts steeper-than-expected quarterly profit slump on tumour drug supply crunch - Reuters","headline":"India's Cipla posts steeper-than-expected quarterly profit slump on tumour drug supply crunch","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}